How to buy ReNeuron Group shares

Own ReNeuron Group shares in just a few minutes. Share price changes are updated daily.

Updated

Fact checked

ReNeuron Group plc (RENE) is a leading biotechnology business based in the UK. ReNeuron Group is listed on the London Stock Exchange (LSE) and employs 62 staff. All prices are listed in pence sterling.

How to buy shares in ReNeuron Group

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: RENE in this case.
  5. Research ReNeuron Group shares. The platform should provide the latest information available.
  6. Buy your ReNeuron Group shares. It's that simple.
The whole process can take as little as 15 minutes.

ReNeuron Group share price

Use our graph to track the performance of RENE stocks over time.

ReNeuron Group shares at a glance

Information last updated 2021-01-23.
52-week range69.1315p - 174.2894p
50-day moving average 95.6794p
200-day moving average 100.8697p
Wall St. target price625p
PE ratio 265
Dividend yield N/A (0%)
Earnings per share (TTM) 0.5p
Promoted
eToro Free Stocks

Invest in ReNeuron Group shares with 0% commission

Other fees may apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • If your trades get copied you can earn extra money
  • Create an account today in a few minutes

Share dealing platform comparison

Table: sorted by promoted deals first
Data indicated here is updated regularly
Name Product Price per trade Frequent trader rate Platform fees Brand description
Fineco
£2.95
£2.95
Zero platform fee
Your first 100 trades are free with Fineco, T&Cs apply.
Fineco Bank is good for share traders and investors looking for a complete platform and wide offer. Capital at risk.
eToro Free Stocks
0% commission, no markup, no ticket fee, no management fee
N/A
Withdrawal fee & GDP to USD deposit conversion
Capital at risk. 0% commission but other fees may apply.
IG
0% commission on US shares, and £3 on UK shares
From £5
£0 - £24 per quarter
IG is good for experienced traders, and offers learning resources for beginners, all with wide access to shares, ETFs and funds. Capital at risk.
Hargreaves Lansdown Fund and Share Account
£11.95
£5.95
No fees
Hargreaves Lansdown is the UK's number one platform for private investors, with the depth of features you'd expect from an established platform. Capital at risk.
Degiro Share Dealing
£1.75 + 0.022% (max £5.00)
£1.75 + 0.022% (max £5.00)
Portfolio transfer fees (in & out)
Degiro is widely seen as one of the best low-cost share brokers, for people who are looking to trade regularly. Capital at risk.
Interactive Investor
From £7.99 on the Investor Service Plan
From £7.99 on the Investor Service Plan
No transfer fees or exit fees. £9.99 a month on the Investor Service Plan
Open an ISA, Trading Account or SIPP you will get £100 of free trades to buy or sell any investment (new customers only).
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum deposit Maximum annual fee Price per trade Brand description
Interactive Investor stocks and shares ISA
Any lump sum or £25 a month
£119.88
£7.99
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
Moneyfarm stocks and shares ISA
£1500
0.75%
£0
Moneyfarm helps you meet your investment goals with fully-managed portfolios designed around you. Capital at risk.
Hargreaves Lansdown stocks and shares ISA
£100
0.45%
£11.95
Hargreaves Lansdown is the UK's biggest wealth manager. It's got everything you'll need, from beginners to experienced investors. Capital at risk.
Nutmeg stocks and shares ISA
£100
0.75%
£0
Nutmeg offers three types of portfolios. Choose the one that goes with your investment style. Capital at risk.
Saxo Markets stocks and shares ISA
No minimum deposit requirement
0.12%
£8.00
Saxo Markets offers a wide access to a range of stocks, ETFs and funds. Capital at risk.
AJ Bell stocks and shares ISA
£500
0.25%
£9.95
AJ Bell is a good all-rounder for people who to choose between shares, funds, ISAs and pensions. Capital at risk.
Fidelity stocks and shares ISA
£1000 or a regular savings plan from £50
0.35%
£10.00
Fidelity is another good all-rounder, offering a good package at a decent price. Not suited for trading shares. Capital at risk.
Legal & General stocks and shares ISA
Legal & General stocks and shares ISA
£100 or £20 a month
0.61%
N/A
Legal & General is a big financial services company which offers insurance, lifetime mortgage, pensions and stocks and shares ISAs. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum investment Choose from Annual fee Brand description
Interactive Investor Pension
Any lump sum or £25 a month
Over 3,000 funds
£10/month
interactive investor is a flat-fee platform, which makes it cost effective for larger portfolios. Capital at risk.
Moneyfarm Pension
£1,500 (initial investment)
7 funds
0.35%-0.75%
Moneyfarm has pensions that are matched against your risk appetite, goals and planned retirement date. Capital at risk.
AJ Bell Pension
£1,000
Over 2,000 funds
0.05-0.25%
AJ Bell has two different pension options, a self managed pension and one that is managed for you. Capital at risk.
PensionBee Pension
No minimum
7 funds
0.5% - 0.95%
Pension Bee is a newbie in the pension market. It helps consolidate your pension plans into one place. Capital at risk.
Hargreaves Lansdown Pension
£100 or £25 a month
2,500 funds
0-0.45%
Hargreaves Lansdown is the UK's biggest wealth manager. It's got three different retirement options. Capital at risk.
Saxo Markets Pension
Saxo Markets Pension
£10
Over 11,000 funds
No annual fee
Saxo Markets gives flexibility and control over your investment strategy. Capital at risk.
Penfold
Penfold
No minimum
4 portfolios
0.75-0.88%
Moneybox Pension
£1
3 funds
0.15% - 0.45% charged monthly
Manage your money with an easy-to-use Moneybox app. Capital at risk.
loading

Compare up to 4 providers

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is it a good time to buy ReNeuron Group stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is ReNeuron Group under- or over-valued?

Valuing ReNeuron Group stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ReNeuron Group's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

ReNeuron Group's P/E ratio

ReNeuron Group's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 265x. In other words, ReNeuron Group shares trade at around 265x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

ReNeuron Group's EBITDA

ReNeuron Group's EBITDA (earnings before interest, taxes, depreciation and amortisation) is £16.4 million.

The EBITDA is a measure of a ReNeuron Group's overall financial performance and is widely used to measure a its profitability.

ReNeuron Group financials

Revenue TTM £112,000
Gross profit TTM £-10,170,000
Return on assets TTM -47.34%
Return on equity TTM -108.79%
Profit margin 0%
Book value 0.208p
Market capitalisation £71.3 million

TTM: trailing 12 months

ReNeuron Group share dividends

We're not expecting ReNeuron Group to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

Have ReNeuron Group's shares ever split?

ReNeuron Group's shares were split on a 1:100 basis on 24 January 2018. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ReNeuron Group shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for ReNeuron Group shares which in turn could have impacted ReNeuron Group's share price.

ReNeuron Group share price volatility

Over the last 12 months, ReNeuron Group's shares have ranged in value from as little as 69.1315p up to 174.2894p. A popular way to gauge a stock's volatility is its "beta".

RENE.LSE volatility(beta: 0.78)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while ReNeuron Group's is 0.7799. This would suggest that ReNeuron Group's shares are less volatile than average (for this exchange).

Win £500 to get your trading started

Subscribe to trending stock alerts for a chance to win

By submitting, you agree to the Finder Privacy and Cookies Policy and Terms of Use

ReNeuron Group overview

ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in Phase IIb clinical trial for stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also developing CTX-derived exosomes, which are Nano-sized packages of information released by CTX cells. ReNeuron Group plc has a research agreement with U.S. biotechnology company in the discovery and development of novel gene silencing-based therapeutics. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

Frequently asked questions

More guides on Finder

  • The best stock trading apps and platforms in the UK

    We’ve taken a look at some of the best trading apps in the UK and explained who they’re best suited to. Our table compares fees and services too.

  • How to buy Transportation and Logistics Systems shares

    Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.

  • How to buy Charlie’s Holdings shares

    Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.

  • How to buy Lemonade shares

    Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.

  • The best stock trading apps and platforms in the UK

    We’ve taken a look at some of the best trading apps in the UK and explained who they’re best suited to. Our table compares fees and services too.

  • How to buy Unity Software shares

    Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor

  • How to buy FuelCell Energy shares

    Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.

  • How to buy CloudCommerce shares

    Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor

  • How to buy Zomedica Pharmaceuticals shares

    Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.

  • How to buy YRC Worldwide shares

    Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site